BEIJING, April 07, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that a research piece titled “Integrated analysis of circulating tumor cells and circulating tumor DNA to detect minimal residual disease in hepatocellular carcinoma” has been published in a highly impactful journal, Clinical and Translational Medicine (ImpactFactor:11.5). The Company’s Mutation Capsule™ technology was used in the publication and the full article can be found here.
Publication in Clinical and Translational Medicine Demonstrates Mutation Capsule™’s potential in MRD Assay Developments
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
